Literature DB >> 24132578

Increased adiponectin associated with poor survival in hepatocellular carcinoma.

Shen-Nien Wang1, Sheau-Fang Yang, Hsin-Hui Tsai, King-Teh Lee, Yao-Tsung Yeh.   

Abstract

BACKGROUND: Alterations of adiponectin (APN), one of the adipokines, have been associated with human cancers. However, the clinical significance and impacts of APN on hepatocellular carcinoma (HCC) remain undetermined.
METHODS: Using immunohistochemistry, expression patterns of APN were semiquantitatively scored and further statistically correlated with clinicopathological characteristics and patient survival. Furthermore, the bioeffects and underlying mechanisms of ectopic APN overexpression were determined in Hep3B and HepG2 cells by XTT, immunoblotting, flowcytometry, and invasion assays with or without chemical inhibitors and neutralization antibody.
RESULTS: We found that cytoplasmic APN staining in 85 cancerous lesions was increased and associated with a poor survival rate (P = 0.007), even when using the Cox regression model (OR = 3.590; 95 % CI = 1.240-10.394; P = 0.018). Ectopic overexpression of APN in Hep3B and HepG2 cells increased proliferation and invasion as well as the levels of p-AKT (Ser473), p-STAT3 (Tyr705), and those downstream, i.e., cyclin D1 and β-catenin. Similar results were also demonstrated in a stable APN-overexpressing clone, HepG2#136. APN neutralization antibody and LY294002 blocked the APN-mediated effects via inhibition of activated AKT.
CONCLUSIONS: Our results suggest that increased APN may contribute to HCC at least in part through its activation of AKT signalling and may serve as a prognostic factor in HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132578     DOI: 10.1007/s00535-013-0898-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  The promoting effect of adiponectin in hepatocellular carcinoma.

Authors:  Ming-Jenn Chen; Yao-Tsung Yeh; King-Teh Lee; Chia-Jung Tsai; Hao-Hsien Lee; Shen-Nien Wang
Journal:  J Surg Oncol       Date:  2012-01-27       Impact factor: 3.454

2.  Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis.

Authors:  Liu Yang; Che-Chang Chan; Oh-Sang Kwon; Songling Liu; Jason McGhee; Stephen A Stimpson; Lihong Z Chen; W Wallace Harrington; William T Symonds; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-06-22       Impact factor: 4.052

3.  Different effects of adiponectin isoforms in human monocytic cells.

Authors:  Markus Neumeier; Johanna Weigert; Andreas Schäffler; Gabriele Wehrwein; Ulf Müller-Ladner; Jürgen Schölmerich; Christian Wrede; Christa Buechler
Journal:  J Leukoc Biol       Date:  2006-01-24       Impact factor: 4.962

4.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Giovanni Tripepi; Francesco A Benedetto; Sebastiano Cutrupi; Saverio Parlongo; Lorenzo S Malatino; Graziella Bonanno; Giuseppe Seminara; Francesco Rapisarda; Pasquale Fatuzzo; Michele Buemi; Giacomo Nicocia; Sachiyo Tanaka; Noriyuki Ouchi; Shinji Kihara; Tohru Funahashi; Yuji Matsuzawa
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

5.  Serum adiponectin levels in cholesterol and pigment cholelithiasis.

Authors:  S-N Wang; Y-T Yeh; M-L Yu; C-L Wang; K-T Lee
Journal:  Br J Surg       Date:  2006-08       Impact factor: 6.939

6.  PTEN-deficient intestinal stem cells initiate intestinal polyposis.

Authors:  Xi C He; Tong Yin; Justin C Grindley; Qiang Tian; Toshiro Sato; W Andy Tao; Raminarao Dirisina; Kimberly S Porter-Westpfahl; Mark Hembree; Teri Johnson; Leanne M Wiedemann; Terrence A Barrett; Leroy Hood; Hong Wu; Linheng Li
Journal:  Nat Genet       Date:  2007-01-21       Impact factor: 38.330

7.  Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.

Authors:  Neeraj K Saxena; Ping P Fu; Arumugam Nagalingam; Jason Wang; Jeffrey Handy; Cynthia Cohen; Mourad Tighiouart; Dipali Sharma; Frank A Anania
Journal:  Gastroenterology       Date:  2010-07-13       Impact factor: 22.682

8.  Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin.

Authors:  Fred Haugen; Christian A Drevon
Journal:  Endocrinology       Date:  2007-08-16       Impact factor: 4.736

9.  Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway.

Authors:  D Barb; A Neuwirth; C S Mantzoros; S P Balk
Journal:  Endocr Relat Cancer       Date:  2007-12       Impact factor: 5.678

10.  Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4.

Authors:  J S Bogan; H F Lodish
Journal:  J Cell Biol       Date:  1999-08-09       Impact factor: 10.539

View more
  14 in total

1.  Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.

Authors:  Jing Shen; Chih-Ching Yeh; Qiao Wang; Irina Gurvich; Abby B Siegel; Regina M Santella
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

2.  Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma.

Authors:  Rong-Rong Song; Xiao-Lin Gu
Journal:  Tumour Biol       Date:  2014-12-11

3.  Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.

Authors:  Abby B Siegel; Abhishek Goyal; Marcela Salomao; Shuang Wang; Valerie Lee; Christine Hsu; Rosa Rodriguez; Dawn L Hershman; Robert S Brown; Alfred I Neugut; Jean Emond; Tomoaki Kato; Benjamin Samstein; David Faleck; Raffi Karagozian
Journal:  Oncology       Date:  2014-10-03       Impact factor: 2.935

Review 4.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

5.  Ubenimex, an APN inhibitor, could serve as an anti‑tumor drug in RT112 and 5637 cells by operating in an Akt‑associated manner.

Authors:  Xiaoqing Wang; Yang Liu; Wei Liu; Yongfei Zhang; Feng Guo; Lijuan Zhang; Mingyu Cui; Shuai Liu; Rongde Wu
Journal:  Mol Med Rep       Date:  2018-01-09       Impact factor: 2.952

6.  Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality.

Authors:  Tomi Akinyemiju; Justin Xavier Moore; Suzanne E Judd; Maria Pisu; Michael Goodman; Virginia J Howard; Leann Long; Monika Safford; Susan C Gilchrist; Mary Cushman
Journal:  Oncotarget       Date:  2018-02-23

Review 7.  Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases.

Authors:  Masaaki Waragai; Gilbert Ho; Yoshiki Takamatsu; Yuka Shimizu; Hiromu Sugino; Shuei Sugama; Takato Takenouchi; Eliezer Masliah; Makoto Hashimoto
Journal:  Drug Discov Today       Date:  2018-05-07       Impact factor: 7.851

8.  Evolving role of adiponectin in cancer-controversies and update.

Authors:  Arnav Katira; Peng H Tan
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

9.  Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis.

Authors:  Jiaxiang Ye; Zhongguo Liang; Qian Liang; Jinyan Zhang; Sufei Mao; Rui Liang
Journal:  Lipids Health Dis       Date:  2015-11-26       Impact factor: 3.876

10.  Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.

Authors:  Yoshio Shimizu; Takafumi Tamura; Akira Kemmochi; Yohei Owada; Yusuke Ozawa; Katsuji Hisakura; Takashi Matsuzaka; Hitoshi Shimano; Noriyuki Nakano; Shingo Sakashita; Tatsuya Oda; Nobuhiro Ohkohchi
Journal:  J Gastroenterol Hepatol       Date:  2020-10-05       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.